CSL Ltd Annual Report 2021

5. CSL Performance and Shareholder Returns 4 T he 2016 Annual Return on Invested Capital figure includes the gain on acquisition of Novartis’ global influenza vaccine business of US$176.1m. The opening share price on 1 July 2016 was A$111.92. The Total Shareholder Return outcome at 30 June 2021 was 0.37%. The Total Dividends per Share is the actual total dividends paid within the financial year. 5.1 Financial Performance from 2015 to 2021 The following graphs 4 summarise key financial performance over the past seven financial years. We have disclosed over a seven year period to align with our ROIC LTI performance measurement period. Cash Inflow FromOperating Activities (millions USD) Annual Return on Invested Capital Closing Share Price (dollars) – AUD Total Shareholder Return (12month %) – AUD Total Dividends Per Share (cents USD) 0 500 1,000 1,500 2,000 2,500 3,000 3,500 4,000 2021 2020 2019 2018 2017 2016 2015 0.0% 5.0% 10.0% 15.0% 20.0% 25.0% 30.0% 35.0% 2021 2020 2019 2018 2017 2016 2015 Net Profit After Tax/ Earnings Per Share (USD) Net Profit After Tax (millions) – USD Earnings Per Share (cents) – USD Closing Share Price (at 30 June AUD)/ Total Shareholder Return 0 70 140 210 280 350 2021 2020 2019 2018 2017 2016 2015 0.0% 10.0% 20.0% 30.0% 40.0% 50.0% 0 500 1,000 1,500 2,000 2,500 2021 2020 2019 2018 2017 2016 2015 0 120 240 360 480 600 0 50 100 150 200 250 2021 2020 2019 2018 2017 2016 2015 CSL Limited Annual Report 2020/21 84 Directors’ Report